Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the languages menu
  5. Go to the help menu
  6. Go to the modules
  7. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Canadian Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Media Room

Contact us

Sanofi Canada

2905 Place Louis-R.-Renaud 
Laval, Quebec, H7V 0A3

Media inquiries

514-856-3860
Toll-free: 1-877-904-2667

Catherine Cunningham
Manager, Corporate and
Brand Communications
514-956-6120

General inquiries

514-956-6200
1-800-363-6364

Content :

New 2010 atrial fibrillation guidelines highlight divide between the Canadian Cardiovascular Society and Common Drug Review’s positions on treating atrial fibrillation

Multaq™ recommended as first-line treatment in new 2010 Atrial Fibrillation Guidelines, but Canadians have limited access to treatment

 

Last update: October 27, 2010

Modules :

Corporate information

Corporate information